Category Archives: Cancer Treatment

Cancer Significant Awareness Offered by Oncotarget

Oncotarget is a famous medical journal in the U.S that majorly talks about oncology aspects. The journal is usually peer-reviewed weekly. Oncotarget Journal was founded in 2010 and is published by Impact Journals. The editors in chief of the magazine are two talented media personalities, Mikhail Blagosklonny and Andrei V. Gudkov.Oncotarget has a goal of providing rapid publication of outstanding research. Today, tumors have become more complicated than before thereby the rate of resisting medication has increased. Oncotarget has therefore gone miles ahead to publish papers containing information on pathology, age-related diseases, endocrinology, immunology, neuroscience, autophagy, physiology, cell death, and chromosome. These topics are posted to educate everyone to a wider scope than just talking about tumors.

Scientists usually partner with the journal and to review and approve the surveys submitted by authors. Some rules are provided by Oncotarget to authors such as the text should be in Times New Roman style, 12pt font size and single spaced. The article should not have a past idea, and the manuscripts should be Microsoft Office, Open Document, WordPerfect or RTF. Moreover, articles submitted online must be less than 15 MBs and also the Heading should not be italicized unless it is a scientific name. For the correct format, an author is expected to use automated reference manager for the article. If an author does not follow these simple rules, the article will not be considered for reviewing its content.

Oncotarget management has many objectives to achieve as a journal. The journal aims at connecting different fields of biomedical science, to remove the bridge between specialties and to increase the benefits of their research by thorough reviewing. Moreover, Oncotarget aims at introducing the application of clinical and basic science and also at allowing significant surveys to be shared widely and quickly because of their great information.Also, Oncotarget has published 370 papers related to oxygen since 2010. Gregg L. Semenza and William G. Kaelin, two staff members of Oncotarget, won the Lasker Award for inventing an oxygen sensing pathway. Oncotarget has helped many people share out their knowledge on oncology. Mikhail Blagosklonny and other members hope Oncotarget will contribute to educating people on cancer until a permanent solution is found.

One of a kind Oncologist newsletter

Oncotarget is a company based on oncological research. Since, its formation, the company has been working to bring innovations in the field of oncology to introduce better treatments and drugs for cancer patients. Oncotarget is basically a newsletter that works on peer to peer review. People from anywhere can share their research work on oncology in this newsletter and can share their knowledge with others. It provides doctors from all over the world a platform to share their work. It is a way of connecting doctors who can interact with each other and can get benefit from each other’s research work. In this way, they make sure they can help the cancer patients in every possible way.

The first newsletter was published by Oncotarget in 2010. Since then it has gained a lot of attention and praise among its readers. Its huge success is due to the fact that it is for doctors and by doctors. That is why it is greatly appreciated by doctors specifically oncologists. These doctors are highly experienced treating patients for many years. They are also aware of the new treatments and innovations in the technology for treatment. Mr. Andrei Gudkov and Mikhail Blagosklonny are its owners. They are highly qualified researchers in the field of oncology and have made incredible progress. Their experience and knowledge have helped them to establish a highly effective newsletter on oncology. The newsletter grew fast in oncology under the guidance of both these men.

This newsletter is weekly and allows open access to all kinds of readers who want to get informed about the latest technologies in the field of oncology or who want to publish their work in oncology. The newsletter is run by two well-known oncologists has attracted the attention of a wide variety of readers all around the world. This has helped a lot in oncology, from discoveries to new treatments and drugs, now many patients can be saved with greater ease. The death of patients suffering from cancer has greatly reduced with the help of this newsletter and to know more click here

 


Eric Lefkofsky Enters the Battle Against Cancer

Advanced technology involving data is allowing one company to take a different route in the fight against cancer. Tempus, which is a company formed by Eric Lefkofsky to battle the disease, intends to give University of Chicago doctors data to help them treat breast cancer patients better. A recent partnership between Tempus and the University of Chicago Medicine was made to advance treatment options in this category even more.

Personalized Treatment Plans

The new merger will allow Tempus to complete a multilevel process involving molecular sequencing and analysis. Once the company finishes its evaluations, it forwards the data to breast cancer specialists who work for the University of Chicago Medicine. These specialists will use this information to develop personalized treatment plans for their patients. According to Tempus, researchers will assess the data from about 1,000 breast cancer patients to start. The company’s goal is to help researchers and doctors spot patterns that will help them determine how a patient will respond to a particular treatment. Tempus believes that this will allow cancer specialists to create better treatment plans, improving patient outcomes for learn more: http://www.chicagobusiness.com/article/20161001/ISSUE01/310019995/can-eric-lefkofsky-save-your-life click here.

Dr. OlufunmilayoOlopade, the University of Chicago’s professor of human genetics and medicine and its global health dean, said, “Although breast cancer is among the most common cancers, there is relatively little accessible data on the millions of patients who have battled the disease.” He went on to say, “This forces too many physicians to make treatment decisions without the benefit of highly specific genetic information that could help them make better informed and precisely targeted decisions.”

Tempus wants to establish the world’s largest clinically annotated molecular information collection for breast cancer treatment. Because the company uses genomic sequencing combined with machine learning, Tempus is able to help doctors develop personalized treatment decisions for patients in real-time.

The partnership with the University of Chicago is the latest collaboration that Tempus has entered into. In its battle against cancer, the company is also working medical facilities like the Mayo Clinic, the Rush University Medical Center, the University of Michigan, Penn Medicine and the Robert H. Lurie Comprehensive Center of Northwestern University.

A Missing Element

To treat breast cancer successfully, medical professionals require data about different things and conditions. According to Lefkofsky, this information is missing from today’s medical research. While there’s plenty of patient data available, the lack of sources that combine therapeutic data with genomic information is lacking.

Lefkofsky said, “Gathering molecular data is one thing, but you also need clinical data. You need therapeutic and outcome response data.” This means that in addition to a patient’s RNA and DNA makeup, medical researchers should be tracking what treatments patients are on and whether or not they’re responding. If a medical researcher is assessing a group of patients who are on a particular drug, then they should be looking into why it is effective for some patients and not others. To do this, they’ll need to consider what may be happening with the patients who are not responding to the treatment. For instance, do they have another medical condition? Or, are they taking an additional drug?

Lefkofsky said, “If you were to go into any of the cancer centers and ask who took Herceptin over two years and how they did, they’d need a grant and at least 90 days. That’s the sort of data that should flow freely between researchers, clinicians and others.”

A Personal Connection

Eric started Tempus after doctors determined that his wife had breast cancer. While learning how to treat her disease, he said that it occurred to him that truck drivers have better information about the best way to perform their jobs than oncologists do. Too often, medical professionals don’t have the information about how well a particular treatment works in other patients.

With Tempus, researchers are creating a technology layer over electronic medical records and the pathology systems, allowing them to accumulate data, scrub it and send a clean report back to the medical professionals. This method makes it quicker and easier for these experts to validate and confirm the data’s results. After completing this step, researchers can combine it into a data pool to detect patterns between the treatments that are being used and the results.

Lefkofsky said, “My goal is to get most people starting in oncology and then those working on neurological disorders to use our platform to collect data for analysis.” He compared it to personalizing vaccines as this is another treatment area that industry experts are trying to improve.

About Tempus

Eric Lefkofsky founded Tempus in 2015. The company’s headquarters are at 600 W. Chicago, which is the same location as Lefkofsky’s other major companies including Groupon, Drivin and Lightbank.

Every year, about a quarter of a million people receive the news that they have breast cancer in the U.S. Treatment centers are looking into new ways to treat the disease. To this end, The Cancer Genome Atlas, or TCGA, which is in partnership with Tempus, has compiled data for slightly more than 1,000 breast cancer patients. TCGA has sequenced and annotated patient information like critical clinical information, treatments used and outcomes. According to researchers, breast cancer genetics are complex. This complexity makes it tough to spot treatment patterns that are therapeutically relevant.

Eric Lefkofsky: Co-Founder and CEO

As the cofounder of Groupon, Lightbank and Uptake Technologies, Erik Lefkofsky is no stranger to starting new companies. Along with being comfortable founding them, Lefkofsky is also successful at establishing companies that are technology-based. He started Echo Global Logistics, which is a firm that oversees technology-enabled transportation and logistics. Lefkofsky started Tempus to help his wife and because he thought that there might be a better way to battle cancer.

A decade ago, he began the Lefkofsky Family Foundation with his wife Liz. The charity is a private one, and its objective is to promote high-impact programs that are created to improve the lives of the people living in the communities it serves. Eric is also a Trustee of Lurie Children’s Hospital of Chicago. He is involved in The Museum of Science and Industry, The Art Institute of Chicago and the World Business Chicago.

A Different Direction

By forming Tempus, Eric Lefkofsky has tossed his hat into the cancer fighting ring. Not only is he using his considerable business acumen to fight the disease, but he is also battling it in a different way. When people shift direction, they often find success. One day, humankind will win the fight against cancer, and it will surprise no one if Lefkofsky is a part of that.